Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 12/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | THRA | P10827 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 2/20 | 0.39 |
| ▸ | PNP | P00491 | 1/20 | 0.38 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28561074 | 0.87 | NPBWR1 (0.47) | NPBWR1MCHR1THRATHRBCRHR1 | |
| SCHEMBL28566985 | 0.87 | NPBWR1 (0.43) | NPBWR1MCHR1THRATHRBCRHR1 | |
| SCHEMBL21749514 | 0.83 | NPBWR1 (0.42) | NPBWR1MCHR1THRATHRBCRHR1 | |
| SCHEMBL21840340 | 0.83 | UCHL1 (0.42) | NPBWR1MCHR1THRATHRBCRHR1 | |
| SCHEMBL21840322 | 0.81 | NPBWR1 (0.42) | NPBWR1MCHR1THRATHRBCRHR1 | |
| SCHEMBL21840315 | 0.80 | THRA (0.46) | NPBWR1MCHR1THRATHRBCRHR1 | |
| SCHEMBL28566363 | 0.80 | PTGDR2 (0.42) | NPBWR1THRB | |
| SCHEMBL21749466 | 0.79 | NPBWR1 (0.38) | NPBWR1MCHR1THRATHRB | |
| SCHEMBL21749425 | 0.79 | NPBWR1 (0.37) | NPBWR1MCHR1THRATHRB | |
| SCHEMBL21749428 | 0.79 | NPBWR1 (0.37) | NPBWR1MCHR1THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112805005-B | Thyroxine receptor beta agonist compounds | 拓臻股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-3840755-B1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | TERNS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250236615-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | Terns, Inc. | 2025-07-24 | — | — | US | disclosed |
| US-20220348561-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | TERNS PHARMACEUTICALS INC (US) | 2022-11-03 | — | — | US | disclosed |
| US-11203587-B2 | Thyroid hormone receptor beta agonist compounds | Terns, Inc. (US) | 2021-12-21 | — | — | US | disclosed |
| US-11203587-B2 | Thyroid hormone receptor beta agonist compounds | Terns, Inc. (US) | 2021-12-21 | — | — | US | disclosed |
| EP-3863635-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | Terns, Inc. (US) | 2021-08-18 | — | — | EP | disclosed |
| EP-3840755-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | Terns, Inc. (US) | 2021-06-30 | — | — | EP | disclosed |
| CN-112839655-A | Thyroid hormone receptor beta agonist compounds | 拓臻股份有限公司 | 2021-05-25 | — | — | CN | disclosed |
| CN-112805005-A | Thyroxine receptor beta agonist compounds | 拓臻股份有限公司 | 2021-05-14 | — | — | CN | disclosed |
| US-10800767-B2 | Thyroid hormone receptor beta agonist compounds | Terns, Inc. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20200115362-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | TERNS PHARMACEUTICALS, INC. (KY) | 2020-04-16 | — | — | US | disclosed |
| US-20200115362-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | TERNS PHARMACEUTICALS, INC. (KY) | 2020-04-16 | — | — | US | disclosed |
| WO-2020041741-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | Terns, Inc. (US) | 2020-02-27 | — | — | WO | disclosed |
| US-20200062742-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | Terns, Inc. | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062742-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | THRB, THRA, TSHR | NPBWR1 158/4885MCHR1 55/4885THRA 2/4885 |
| US-20220348561-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | THRB, THRA, TSHR | NPBWR1 164/4885MCHR1 59/4885THRA 2/4885 |
| US-20200115362-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | THRB, THRA, TSHR | NPBWR1 164/4885MCHR1 59/4885THRA 2/4885 |
| US-20250236615-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | THRB, THRA, TSHR | NPBWR1 158/4885MCHR1 55/4885THRA 2/4885 |
| US-11203587-B2 | Thyroid hormone receptor beta agonist compounds | THRB, THRA, TSHR | NPBWR1 164/4885MCHR1 59/4885THRA 2/4885 |
| US-10800767-B2 | Thyroid hormone receptor beta agonist compounds | THRB, THRA, TSHR | NPBWR1 158/4885MCHR1 55/4885THRA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.